MARKET

SRPT

SRPT

Sarepta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

137.76
-6.20
-4.31%
After Hours: 137.76 0 0.00% 17:27 09/24 EDT
OPEN
142.35
PREV CLOSE
143.96
HIGH
143.53
LOW
134.52
VOLUME
969.93K
TURNOVER
--
52 WEEK HIGH
175.00
52 WEEK LOW
72.05
MARKET CAP
10.81B
P/E (TTM)
-19.6035
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Buy the dip in biotechs - RBC
In a note RBC regards yesterday's selloff in biotechs as an "especially attractive entry point" for leading names such names as Gilead Sciences ([[GILD]] -2.1%), Sarepta Therapeutics ([[SRPT]] -1.8%) and
Seekingalpha · 3d ago
How Pfizer Plans to Lead the Industry in Gene Therapies
The drugmaker is eager to recast itself as a high-multiple growth stock. The expected growth will be fired up by 25 product launches, which Pfizer is explaining in two days of online talks.
Barrons.com · 09/15 20:11
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 21 recipients of Route 79, The Duchenne Scholarship Program. This is the third year of the scholarship program, which was created
GlobeNewswire · 09/15 12:30
Long-term functional data from Sarepta Therapeutics Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
\-- Webcast conference call to be held on Monday, Sept. 28, 2020 at 8:30 a.m. Eastern Time --\-- Additional poster presentations at WMS will highlight data from Sarepta’s RNA and gene therapy programs --CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT
GlobeNewswire · 09/14 13:30
FDA Delays Start of Sareptas Gene Therapy Trial. That Doesnt Faze the Stocks Bulls.
The delay will cost the company a few months at most, analysts say.
Barrons.com · 09/10 15:19
Sarepta Therapeutics Stock Falls On Delay In Quest For Muscular Dystrophy Treatment
Investor's Business Daily · 09/10 15:16
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Shares of Sarepta Therapeutics Inc. undefined were down 0.7% in premarket trading on Thursday, the day after the company said it had submitted a written...
MarketWatch · 09/10 12:38
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRPT. Analyze the recent business situations of Sarepta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRPT stock price target is 192.50 with a high estimate of 221.00 and a low estimate of 150.00.
EPS
Institutional Holdings
Institutions: 577
Institutional Holdings: 78.20M
% Owned: 99.61%
Shares Outstanding: 78.51M
TypeInstitutionsShares
Increased
127
5.83M
New
132
-799.73K
Decreased
124
5.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
M. Kathleen Behrens
President/Chief Executive Officer/Director
Douglas Ingram
Chief Financial Officer/Chief Accounting Officer
Joseph Bratica
Executive Vice President/General Counsel/Secretary
David Howton
Executive Vice President
William Ciambrone
Executive Vice President
Alexander Cumbo
Executive Vice President
Gilmore O'Neill
Independent Director
Richard Barry
Independent Director
Mary Gray
Independent Director
John Martin
Independent Director
Claude Nicaise
Independent Director
Hans Wigzell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SRPT
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.